Immucell (ICCC) Asset Utilization Ratio (2011 - 2026)
Immucell's (ICCC) quarterly Asset Utilization Ratio came in at 0.63 in Q4 2025, up 33.05% YoY from 0.47 in Q4 2024, and up 4.27% on a QoQ basis from 0.6 in Q3 2025.
Immucell (ICCC) Asset Utilization Ratio (2011 - 2026) Analysis & Trends
Immucell (ICCC) has 15 years of Asset Utilization Ratio data on file, last reported at 0.63 in Q4 2025.
- Quarterly Asset Utilization Ratio rose 33.05% year-over-year to 0.63 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.63 (up 33.05% YoY) and the FY2025 annual result came in at 0.63, up 5.86% from the prior year.
- Asset Utilization Ratio rose to 0.63 in Q4 2025, from 0.6 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.63 in Q4 2025 to a low of 0.28 in Q4 2023.
- A 5-year average of 0.42 and a median of 0.4 in 2022 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2023 — Asset Utilization Ratio sank 31.15% — and 2025, when it soared 104.48%.
- Tracing ICCC's Asset Utilization Ratio over 5 years: stood at 0.43 in 2021, then slipped by 6.22% to 0.41 in 2022, then sank by 31.15% to 0.28 in 2023, then jumped by 68.06% to 0.47 in 2024, then jumped by 33.05% to 0.63 in 2025.
- The last three Asset Utilization Ratio figures came in at 0.63 (Q4 2025), 0.6 (Q3 2025), and 0.61 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 0.13 |
| 10 | Immucell | 95.12 Mn | 86.26 Mn | 2.44 Mn | 0.60 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.60 |
| Dec 31, 2025 | 0.63 |
| Sep 30, 2025 | 0.60 |
| Jun 30, 2025 | 0.61 |
| Mar 31, 2025 | 0.48 |
| Dec 31, 2024 | 0.47 |
| Sep 30, 2024 | 0.31 |
| Jun 30, 2024 | 0.30 |
| Mar 31, 2024 | 0.37 |
| Dec 31, 2023 | 0.28 |
| Sep 30, 2023 | 0.37 |
| Jun 30, 2023 | 0.36 |
| Mar 31, 2023 | 0.36 |
| Dec 31, 2022 | 0.41 |
| Sep 30, 2022 | 0.44 |
| Jun 30, 2022 | 0.44 |
| Mar 31, 2022 | 0.46 |
| Dec 31, 2021 | 0.43 |
| Sep 30, 2021 | 0.40 |
| Jun 30, 2021 | 0.39 |